Chimeric antigen receptor (CAR) T-cells might be a promising therapeutic option for TP53-mutant AML/MDS. However, the impact of TP53 deficiency in AML cells on the efficacy of CAR T-cells is unknown. We here show that CAR T-cells engaging TP53-deficient leukemia cells exhibit a prolonged ...
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment strategies for TP53-mutant MDS and AML. David Sallman, MD A clinical trial evaluating duplex TP53 minimal residual disease (MRD)...
David Sallman, MD, Moffitt Cancer Center, discusses the study design, objectives, and rationale behind using eprenetapopt and azacitidine together for the treatment of in patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML...
we investigated erythroid–myeloid-associated transcription in the BeatAML and The Cancer Genome Atlas (TCGA) cohorts26,27. Erythroid scores were increased inTP53mutant compared toTP53-WT AML, whereas there was no significant difference in myeloid scores (Fig.2e–f,...
Title:Shattuck Labs Additional Interim Data from Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline HR-MDS and TP53m AML Patients Date & Time: Friday, June 14, 2024 at 7:30 a.m. ET Webcast Details:https://lifescievents.com/event/shattucklabseha2024/ ...
Mutations in the TP53 tumour suppressor gene are found in ~50% of human cancers [1–6]. TP53 functions as a transcription factor that directly regulates the expression of ~500 genes, some of them involved in cell cycle arrest/cell senescence, apopto
In this study, we analyzed 240 patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who underwent HSCT. We aimed to identify the patients who benefit most from HSCT. The primary outcome was progression-free survival (PFS). Of the cohort, 52% had AML and...
Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patientsdoi:10.1007/s12185-025-03951-zAllogeneic hematopoietic stem cell transplantation is recommended for TP53 -mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) despite a high ...
Background: TP53 mutation (TP53mut) confers adverse prognosis in acute myeloid leukemia (AML) with limited response to chemotherapy. 10-day decitabine (DEC) regimen has shown high efficacy in TP53mut AML (Welch et al. NEJM 2016). We hypothesized that adding venetoclax (VEN) to 10-day DEC ...
In conclusion, patients with TP53-mutant AML have poor prognoses under current treatment strategies and MR gene mutations are associated with a more favorable survival. Therefore, further studies are needed to improve the survival rates in this population....